A multicenter, single arm phase 2 study to examine efficacy and cerebrospinal fluid transitivity of Osimertinib in leptomeningeal carcinomatosis (LMC) patients with non-small cell lung cancer harboring EGFR mutation
Latest Information Update: 11 Oct 2019
At a glance
- Drugs Osimertinib (Primary)
- Indications Meningeal carcinomatosis
- Focus Therapeutic Use
- 10 Sep 2019 Results (n=6) were presented at the 20th World Conference on Lung Cancer
- 04 Oct 2016 New trial record
- 03 Oct 2016 Status changed from not yet recruiting to recruiting.